Trending

trial

Cancer market commentary: Roche’s Tecentriq muscles into NSCLC

Cancer market commentary: Roche’s Tecentriq muscles into NSCLC

Roche’s PD-L1 drug has generated impressive data in second line lung cancer

X

Cancer market commentary: Roche’s Tecentriq muscles into NSCLC

https://pharmaphorum.com/esmo-2016/cancer-market-commentary-roches-tecentriq-muscles-nsclc/

Eye on ESMO: Day 2 – gamechangers take centre stage

Eye on ESMO: Day 2 – gamechangers take centre stage

Novartis’ phase 3 advanced breast cancer therapy ribociclib shows promise

X

Eye on ESMO: Day 2 – gamechangers take centre stage

https://pharmaphorum.com/esmo-2016/eye-esmo-day-two-gamechangers-take-centre-stage/

VIDEO: Immunotherapy monitoring: Is Immuno-PET the solution?

VIDEO: Immunotherapy monitoring: Is Immuno-PET the solution?

The rapid advancement of immunotherapy in recent years has presented a number of challenges to pharmaceutical firms looking

X

VIDEO: Immunotherapy monitoring: Is Immuno-PET the solution?

https://pharmaphorum.com/partner-content-oncology/immuno-pet-offer-solution-effective-immunotherapy-monitoring/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com